Skip to main content

Table 4 Descriptive comparison of disease activity and medications in use at baseline and after the third qHPV vaccine dose

From: Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in patients with juvenile dermatomyositis: a real-world multicentre study

CMAS (n = 40)a Cutaneous manifestations (n = 40)a Medications in use (n = 40)a
    Rash Gottron’s papules Heliotrope   
Definition n (%) Definition n (%) n (%) n (%) Definition n (%)
Stable with CMAS ≥48 24 (60.0) Stable without cutaneous lesion 31 (77.5) 27 (67.5) 33 (82.5) Stable without medication 11 (27.5)
Stable with CMAS <48 11 (27.5) Stable with cutaneous lesion 3 (7.5) 9 (22.5) 2 (5.0) Stable with medication 9 (22.5)
CMAS Improvement 5 (12.5) Improvement of cutaneous lesion 5 (12.5) 3 (7.5) 3 (7.5) Decreased medication 14 (35.0)
CMAS Worsening 0 (0.0) Worsening or new-onset of cutaneous lesion 1 (2.5) 1 (2.5) 2 (5.0) Increased medication 6 (15.0)
  1. CMAS Childhood Myositis Activity Score, qHPV quadrivalent human papillomavirus vaccine
  2. aData from 40 patients were available for comparison between the baseline visit and the visit after the third vaccine dose